Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 15/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.57 |
| ▸ | TSHR | P16473 | 9/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20071144 | 0.85 | CYP2D6 (0.63) | CYP2D6CYP1A2TSHRCYP3A4HIF1A | |
| SCHEMBL18713030 | 0.79 | HRH3 (0.43) | CYP2D6CYP1A2TSHRCYP3A4HIF1A | |
| SCHEMBL20153203 | 0.79 | RET (0.34) | CYP2D6CYP1A2TSHRCYP3A4HIF1A | |
| SCHEMBL25124519 | 0.78 | CYP2D6 (0.31) | CYP2D6CYP1A2TSHRCYP3A4USP2 | |
| SCHEMBL25551498 | 0.77 | CYP2D6 (0.52) | CYP2D6CYP1A2TSHRCYP3A4HIF1A | |
| SCHEMBL20353665 | 0.76 | KDM4E (0.37) | CYP2D6CYP1A2TSHRCYP3A4HIF1A | |
| SCHEMBL24688706 | 0.74 | CYP3A4 (0.35) | CYP2D6CYP1A2TSHRCYP3A4USP2 | |
| SCHEMBL19501245 | 0.74 | — | — | |
| SCHEMBL27281797 | 0.74 | — | — | |
| SCHEMBL27283006 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3706/4885CYP1A2 3812/4885TSHR 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.